España
Acceder
  1. Inicio
  2. Perfil de raclit
  3. Contenidos recomendados por raclit

Contenidos recomendados por raclit

raclit 19/11/12 22:15
Ha respondido al tema Farmas USA
AMRN, still hindered by lack of M&A Activity and NCE Designation http://www.biomedreports.com/20121119113668/amarin-still-hindered-by-lack-of-maa-activity-and-nce-designation.html más bla bla bla
Ir a respuesta
raclit 18/11/12 18:57
Ha respondido al tema Farmas USA
Muuy buen dia pasamos!!!corto de tiempo, a ver si otronquedada se hace en un sitio mas central y se apunta mas gente
Ir a respuesta
raclit 09/11/12 22:25
Ha respondido al tema Farmas USA
ARNA, Form 10-Q for ARENA PHARMACEUTICALS INC http://biz.yahoo.com/e/121109/arna10-q.html
Ir a respuesta
raclit 09/11/12 00:59
Ha respondido al tema Farmas USA
Ya ves, si todo pinta bien!! vengaaaa unas alegrias pa nuestros cuerpos, que ya nos toca!!
Ir a respuesta
raclit 07/11/12 16:04
Ha respondido al tema Farmas USA
recordatorio de fechas http://seekingalpha.com/article/986071-biotech-catalyst-calendar-4-stocks-to-watch-in-november
Ir a respuesta
raclit 06/11/12 02:27
Ha respondido al tema Threshold Pharmaceuticals, Inc (THLD): Opiniones
It's very interesting that with a great financial condition, a lot of cash with no debts, and a vast amount of test cases with great potential THLD is still lagging behind in stock price. What are people and other big firms waiting for?
Ir a respuesta
raclit 05/11/12 22:51
Ha respondido al tema Threshold Pharmaceuticals, Inc (THLD): Opiniones
yo, esque estoy a ver si consigo meter todo en saxo, que ahora tengo 4 brokers ING, shares a 6.3 Clicktrade cfds a 5.9 Saxo las de hoy a 4.1 vaaaariedad señores, variiedad!!jaja la putada es que quería pasar los cfds de click a saxo para promediar y vender y recomprar más abajo, pero resulta que los cfds nos e pueden traspasar y yo no lo sabía
Ir a respuesta
raclit 05/11/12 22:19
Ha respondido al tema Threshold Pharmaceuticals, Inc (THLD): Opiniones
opinión sobre THLD. Si es que no hay más que sacar ya, está todo dicho There are plenty of possible reasons. Tax-loss selling is one. People are also waiting on Celgene's Phase 3 results from Abraxane in pancreatic is another. As there re no pending updates likely from any of their current trials management doesn't have much to say that wasn't said countless times fom July to October at various conferences. It is true that they have payments from Merck but not much more to report than that. Investors will not pay for future royalties until they are paid so that shouldn't be considered a fact until THLD cashes the check. Lastly I would add that the biotech sector which has had blistering '12 performance looks like it 's undergoing a nice bout of profit-taking. Other than mid & large cap names in the sector not much else in biotech is currently working, especilly in the microcap sector.
Ir a respuesta